DOCSLIB.ORG

Proposal for the Inclusion of Mesna (Sodium 2-Mercaptoethane Sulfonate)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proposal for the Inclusion of Mesna (Sodium 2-Mercaptoethane Sulfonate) 17th Expert Committee on the Selection and Use of Essential Medicines Geneva, 2009 Proposal for the inclusion of mesna (sodium 2-mercaptoethane sulfonate) for the prevention of ifosfamide and cyclophosphamide (oxazaphosphorine cytotoxics) induced haemorrhagic cystitis FINAL REPORT Paul A. Carless BHSc, MMedSc.(Clin.Epid) Discipline of Clinical Pharmacology School of Medicine and Public Health Faculty of Health University of Newcastle Level 5, Clinical Sciences Building, NM2 Newcastle Mater Hospital Edith Street, Waratah, 2298 New South Wales AUSTRALIA Tel +61-02-49211726 Fax + 61-02-49602088 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 1. Summary statement of the proposal Mesna is proposed for the inclusion in the World Health Organisation (WHO) Model List of Essential Medicines for the prevention of oxazaphosphorine-induced (ifosfamide and cyclophosphamide) hemorrhagic cystitis. 2. Name of focal point in WHO submitting or supporting the application 3. Name of the organisation(s) consulted and/or supporting the application Discipline of Clinical Pharmacology, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Level 5, Clinical Sciences Building, NM2, Newcastle Mater Hospital, Edith Street, Waratah, 2298, New South Wales, Australia. 4. International Nonpropriety Name (INN, generic name) of the medicine Mesna (Chemical name: sodium 2-mercaptoethane sulfonate). 5. Formulation proposed for inclusion Tablets: 400 mg, 600 mg Injection: 400 mg / 4 ml, 1g / 10 ml 6. International availability – sources, if possible manufactures (Appendix A) Mesna is marketed under 14 different trade names in 32 countries worldwide. A detailed list of manufacturers and distributors is presented in Appendix A. 7. Whether listing is requested as an individual medicine or as an example of a therapeutic group Listing is requested on the Model List of Essential Medicines as an individual medicine. 8. Information supporting the public health relevance (epidemiological information on disease burden, assessment of current use, target population) 8.1 Global burden of disease The global burden of cancer continues to increase with the number of new cases expected to grow by 50% over the next 20 years to reach 15 million by 2020 (World Cancer Report 2003).1 Data available from the International Agency for Research on Cancer (IARC: Globocan 2002)2 indicates that in 2002 cancer claimed 6.7 million lives worldwide. In 2002 there were 10.9 million new cases of cancer diagnosed worldwide and between 1998-2002 there were 24.6 million people living with cancer. Cancer is the second leading cause of death in developed countries and is among the three leading causes of death in developing countries. A summary of global cancer deaths by region is presented in Table 1.1. 1 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 Table 1.1: Summary of worldwide cancer deaths by region Region Deaths Predicted deaths 2002 2020 North America 631,900 951,400 Central America, South America, and Carribbean 479,900 833,800 Northern Europe 241,100 297,600 Central and Eastern Europe 637,000 742,800 Western Europe 475,100 617,100 Southern Europe 348,400 427,300 Eastern Asia 2,016,300 3,223,700 South-Central Asia 845,200 1,389,800 South-Eastern Asia 363,400 709,300 Northern Africa and Western Asia 224,000 389,200 Sub-Saharan Africa 412,100 626,400 Oceania 49,500 77,300 Total 6,723,900 10,285,700 Source: IARC, Globocan 20022 More recent data indicates that in 2005 cancer killed 7.6 million people which accounts for around 13% of all deaths worldwide.3 Of all these cancer deaths 70% occurered in low and middle income countries. The WHO predicts that deaths from cancer in the world will continue to rise with an estimated 9 million people dying from cancer in 2015 and by 2030 the number of deaths from cancer is anticipated to be 11.4 million of whom 8.9 million will be from low-middle income countries compared to 2.5 million will be from high income countries. A summary of the types of cancer leading to overall cancer mortality in 2002 is presented in Table 1.2 and Figure 1.1. Table 1.2: Summary of the types of cancer leading to overall cancer mortality in 2002 Type of cancer Number of cases Mouth and oropharynx cancers 317,894 Oesophagus cancer 446,166 Stomach cancer 850,401 Colon and rectum cancers 622,256 Liver cancer 618,124 Pancreas cancer 230,957 Trachea, bronchus, lung cancers 1,243,199 Melanoma and other skin cancers 66,034 Breast cancer 477,196 Cervix uteri cancer 238,814 Corpus uteri cancer 71,387 Ovary cancer 134,623 Prostate cancer 269,292 Bladder cancer 178,850 Lymphomas, multiple myeloma 334,421 Leukemia 264,229 Other malignant neoplasms 756,924 Other neoplasms 148,910 Source: Global Action Against Cancer - Updated Edition 20053 2 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 Kidney 34 56 Ovary 114 Pancreas 101 111 Leukaemia 85 109 Oral cavity 47 80 Non-Hodgkin lymphoma 67 93 Bladder 33 99 Mortality Female 110 Oesophagus Mortality Male 226 Cervix uteri 233 Pr os tate 204 Liver 164 383 Stomach 241 405 Colorectum 237 254 Breast 372 Lung 292 810 0 100 200 300 400 500 600 700 800 900 Number (Thousands) Fig. 1.1 Mortality of the most common cancers worldwide by sex. Source: World Cancer Report 2003.1 In terms of incidence, the most common cancers worldwide (excluding non-melanoma skin cancers) are lung (12.3% of all cancers), breast (10.4%) and colorectum (9.4%)(Fig.1.2). As stated in the World Cancer Report (2003),1 for any disease the relationship of incidence to mortality is an indication of prognosis, similar incidence and mortality rates being indicative of an essentially fatal condition. Thus, lung cancer is the largest single cause of deaths from cancer in the world (1.1 million annually), since it is almost invariably associated with poor prognosis. 3 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 Kidney 70 118 Ovary 192 Pancreas 100 115 Leukaemia 112 144 Oral cavity 97 169 Non-Hodgkin lymphoma 120 166 Bladder 76 259 Oesophagus 133 278 Incidence Female 470 Cervix uteri Incidence Male Pr os tate 542 Liver 165 398 Stomach 317 558 Colorec tum 445 498 Breast 1,050 Lung 337 901 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 Number (Thousands) Fig. 1.2 Incidence of the most common cancers worldwide by sex. Source: World Cancer Report 2003.1 The burden of cancer is not distributed evenly between the developing and developed world, with specific cancer types displaying different patterns of distribution (Fig.1.3 and 1.4). As discussed in the World Cancer Report (2003),1 many differences in the distribution of cancer between regions are explicable with reference to etiological factors. In developing countries for example, populations are vulnerable to cancers in which infectious agents (and associated non-malignant diseases) play a major role. These include cancers of the stomach, uterine cervix, liver and possibly oesophagus. Whereas other cancers such as colorectal and prostate cancers, the burden of disease falls disproportionately on the developed world. 4 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 Male Brain, etc 59 41 Other pharynx 64 37 Pancreas 50 66 Kidney 39 79 Larynx 80 62 Leukaemia 86 58 Non-Hodgkin lymphoma 86 Less developed 80 Oral cavity 110 More developed 60 Bladder 96 164 Oesophagus 224 55 Liver 325 73 Colorectum 180 319 Pr os tate 127 416 Stomach 350 208 Lung 431 471 0 50 100 150 200 250 300 350 400 450 500 Number (Thousands) Fig. 1.3 Comparison of the most common cancers in males in more and less developed countries in 2000. NHL = Non Hodgkin lymphoma. Source: World Cancer Report, 2003.1 Female Bladder 27 48 Thyroid 53 35 Oral cavity 72 24 Pancreas 39 61 Leukaemia 65 47 Non-Hodgkin lymphoma 54 66 Oesophagus 117 16 Liver 132 Less developed 33 Corpus uteri 75 More developed 113 Ovary 101 91 Stomach 192 125 Lung 161 175 Colorectum 154 291 Cervix uteri 379 91 Breast 471 579 0 100 200 300 400 500 600 700 Number (Thousands) Fig. 1.4 Comparison of the most common cancers in females in more and less developed countries in 2000. NHL = Non Hodgkin lymphoma. Source: World Cancer Report, 2003.1 Data available from the IARC (Globocan 2002)2 indicates that more than 160,000 children worldwide are diagnosed with cancer each year, and it is estimated that 90,000 will eventually die of cancer. In the United States cancer is the second leading cause of death 5 WHO EML - Final Report - MESNA (sodium 2-mercaptoethane sulfonate) – February 2008 among children between the ages of 1 and 14 years.4 The principle subtype of paedatric cancer in affluent societies is acute leukaemia where the incidence rate is within the range of 30-45 per 106 children per year.5 In the United Kingdom there around 500 new cases of acute leukaemia diagnosed each year in children up to 15 years. Other common childhood cancers include cancer of the brain and other nervous system cancers, soft tissue sarcomas, non- Hodgkin Lymphoma, and renal (Wilms) tumors. In the United States advances in the treatment of childhood cancers have led to an improved 5-year survival rate from 56% for patients diagnosed in 1974-1976 to 79% in children diagnosed with cancer in 1995 to 2001.4 In the case of acute leukaemia, controlled clinical trials of chemotherapy in the United States and Europe have steadily improved the survival of children to 85%.5 However, not all children worldwide have access to optimal treatment.
Load more

Recommended publications
  • ©Ferrata Storti Foundation
    Malignant Lymphomas Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and research paper mobilizing therapy for haematologica 2002; 87:816-821 relapsed/refractory lymphoma http://www.haematologica.ws/2002_08/816.htm patients PIER LUIGI ZINZANI, MONICA TANI, ANNA LIA MOLINARI,* VITTORIO STEFONI, ELIANA ZUFFA,* LAPO ALINARI, ANNALISA GABRIELE, FRANCESCA BONIFAZI, Institute of Hematology and Medical Oncology PATRIZIA ALBERTINI, MARZIA SALVUCCI,* SANTE TURA, “L. e A. Seràgnoli”, University of Bologna; MICHELE BACCARANI *Division of Hematology, Ravenna Hospital, Ravenna, Italy Background and Objectives. Therapy for relapsed/refrac- lthough advanced stage Hodgkin’s disease tory lymphomas should be based only on drugs not (HD) and some aggressive non-Hodgkin’s included in the front-line chemotherapy regimens. We Alymphomas (NHL) are potentially curable adopted the strategy of using salvage chemotherapy to with standard chemotherapy, many patients either debulk disease and simultaneously mobilize stem cells, relapse or never achieve remission.1,2 One way of using a regimen based on ifosfamide and etoposide, improving this situation could be to intensify (drugs not usually used for front-line treatment). front-line chemotherapy, either by dose-escala- tion of conventional therapy3 or by adding high- Design and Methods. A three-drug combination of ifos- famide, epirubicin and etoposide (IEV) was used to treat dose chemotherapy with peripheral blood stem cell 4,5 62 patients with relapsing or refractory aggressive non- (PBSC) rescue. Whereas treatment of relapsing Hodgkin’s lymphoma (NHL; n=51) or Hodgkin’s disease disease with conventional chemo- and/or radiation (HD; n=11). Forty-five of the patients were studied for the therapy is unsatisfactory, especially in those feasibility of peripheral blood stem cell (PBSC) harvest.
    [Show full text]
  • VIP - Ifosfamide, Cisplatin and Etoposide
    THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Systemic Anti Cancer Treatment Protocol VIP - Ifosfamide, Cisplatin and Etoposide PROTOCOL REF: MPHA VIPGC (Version No: 1.1) Approved for use in: Germ cell Dosage: Drug Dosage Route Frequency Etoposide 75mg/m2 days 1 to 5 IV Every 21 days Cisplatin 20mg/m2 days 1 to 5 IV Every 21 days Mesna 200mg/m2 days 1 to 5 IV Every 21 days Ifosfamide 1500mg/m2 + 1500mg/m2 IV Every 21 days +Mesna days 1 to 5 Mesna 1200mg 1 to 5 Oral Every 21 days Supportive treatments: Domperidone 10mg oral tablets, up to 3 times a day or as required Dexamethasone tablets, 4mg twice daily for 3 days Filgrastim 30MU or 48MU subcutaneous injection daily for 7 days starting on day 6, repeat FBC and continue for further 7 days if neutrophil count has not recovered to 1.0 x 109/L Extravasation risk: Etoposide – Irritant Cisplatin – Exfoliant Ifosfamide - Neutral Issue Date: 31st January 2019 Review Date: January 2022 Page 1 of 10 Protocol reference: MPHAVIPGC Author: Nick Armitage Authorised by: Dr. Ali Version No:1.1 THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Administration: Day Drug Dosage Route Diluent and Rate 1 Dexamethasone 8mg PO 30 mins before chemotherapy 1 Ondansetron 16mg PO 30 mins before chemotherapy 1 Etoposide 75mg/m2 IV In 250 to 1000mL sodium chloride 0.9% over 60 minutes 1 Cisplatin 20mg/m2 IV 1000mL 0.9% sodium chloride over 90 minutes 1 Mesna 200mg/m2 IV In 500mL sodium chloride 0.9% over 15 minutes 1 Ifosfamide + Mesna 1500mg/m2 IV In 1000mL sodium chloride + 0.9% over 4 hours 1500mg/m2
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck
    ANTICANCER RESEARCH 29: 5137-5142 (2009) Docetaxel, Ifosfamide and Cisplatin (DIP) in Squamous Cell Carcinoma of the Head and Neck POL M. SPECENIER1, JAN VAN DEN BRANDE1, DIRK SCHRIJVERS1,2, MANON T. HUIZING1, SEVILAY ALTINTAS1, JOKE DYCK1, DANIELLE VAN DEN WEYNGAERT3, CARL VAN LAER4 and JAN B. VERMORKEN1 Departments of 1Medical Oncology, 3Radiotherapy and 4Otolaryngology, Antwerp University Hospital, Edegem; 2Department of Medical Oncology, ZNA Middelheim, Antwerp, Belgium Abstract. Background: Docetaxel, ifosfamide and cisplatin response, 19 partial responses, 1 stable disease); the complete have all shown activity in squamous cell carcinoma of the head response rate increased to 42% after 4 × DIP. No dose or and neck (SCCHN). The optimal combination of the three drugs sequence effect was evident. The minimum follow-up of the is, however, unknown. Considering the favorable results of surviving patients was 51 months, with median relapse-free taxane-containing triplets as induction chemotherapy in locally survival of 13.8 months and median overall survival of 18.8 advanced (LA) SCCHN, DIP (docetaxel, ifosfamide, cisplatin) months. Only four patients relapsed at distant sites. Conclusion: was studied in this setting as part of a phase I dose- and DIP is highly active in previously untreated LA SCCHN, sequence-exploring study. Patients and Methods: D (60 or 75 however, toxicity of DIP in this population is substantial. mg/m2) was given by 60-min infusion on day 1, I (1000 mg/m2/day), with mesna until 12 hours after I, by 24-h infusion For over two decades, cisplatin has been the backbone of days 1-5, and P (50 or 75 mg/m2) by 24-h infusion on days 1 or chemotherapeutic regimens which are used for the treatment 5.
    [Show full text]
  • Arsenic Trioxide Is Highly Cytotoxic to Small Cell Lung Carcinoma Cells
    160 Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells 1 1 Helen M. Pettersson, Alexander Pietras, effect of As2O3 on SCLC growth, as suggested by an Matilda Munksgaard Persson,1 Jenny Karlsson,1 increase in neuroendocrine markers in cultured cells. [Mol Leif Johansson,2 Maria C. Shoshan,3 Cancer Ther 2009;8(1):160–70] and Sven Pa˚hlman1 1Center for Molecular Pathology, CREATE Health and 2Division of Introduction Pathology, Department of Laboratory Medicine, Lund University, 3 Lung cancer is the most frequent cause of cancer deaths University Hospital MAS, Malmo¨, Sweden; and Department of f Oncology-Pathology, Cancer Center Karolinska, Karolinska worldwide and results in 1 million deaths each year (1). Institute and Hospital, Stockholm, Sweden Despite novel treatment strategies, the 5-year survival rate of lung cancer patients is only f15%. Small cell lung carcinoma (SCLC) accounts for 15% to 20% of all lung Abstract cancers diagnosed and is a very aggressive malignancy Small cell lung carcinoma (SCLC) is an extremely with early metastatic spread (2). Despite an initially high aggressive form of cancer and current treatment protocols rate of response to chemotherapy, which currently com- are insufficient. SCLC have neuroendocrine characteristics bines a platinum-based drug with another cytotoxic drug and show phenotypical similarities to the childhood tumor (3, 4), relapses occur in the absolute majority of SCLC neuroblastoma. As multidrug-resistant neuroblastoma patients. At relapse, the efficacy of further chemotherapy is cells are highly sensitive to arsenic trioxide (As2O3) poor and the need for alternative treatments is obvious. in vitro and in vivo, we here studied the cytotoxic effects Arsenic-containing compounds have been used in tradi- of As2O3 on SCLC cells.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Cons Folio Folio C.G. Fecha De Recepcion Asunto* Area De
    FECHA DE CONS FOLIO FOLIO C.G. ASUNTO* AREA DE ATENCION RECEPCION * Para efectos de homologación de la información, estos apartados se encuentran en proceso de elaboración y serán completados antes del mes de marzo de 2018 1 1 2 2 3 3 4 4 5 5 6 6 7 7 8 8 9 9 10 10 OFICIO SEC38/0001/2014 EL C. HILARIO ANDRES RIVERA BOLAÑOS, SOLICITA SE LE BRINDEN DIRECCIÓN GENERAL DE 11 14 11 07/01/2014 FACILIDADES A LA C. ELIZABETH M. COMO ADMINISTRACIÓN. DELEGADA DE TRABAJO JUICIO AMPARO 663/2013-I-B. BUSQUEDA DE DIRECCIÓN GENERAL DE 12 21 12 07/01/2014 DOMICILIO. ADMINISTRACIÓN. OFICIO DGSMU/5959/2013, POR EL DR. JOSE ALFREDO JIMÉNEZ DOUGLAS, SECRETARIA DE SALUD INVITACIÓN A 4A SESIÓN ORDINARIA DEL DIRECCIÓN GENERAL DE 13 22 13 07/01/2014 COMITÉ TÉCNICO DE EVALUACIÓN Y SEGUIMIENTO DESARROLLO SOCIAL. DEL PROGRAMA DE ATENCIÓN INTEGRAL DEL CANCER DE MAMA, EL 8 DE ENERO 2014 OFICIO SF/TDF/054/2014 POR EL MTRO. EMILIO 14 ** BARRIGA DELGADO, TESORERO DEL D.F. INVITACIÓN 14 23 CANCELAD 07/01/2014 A REUNION OPERATIVA DEL FONDO DE O APORTACIONES PARA LA INFRAESTRUCTURA SOCIAL, EL 9 DE ENERO 2014. OFICIO CIDT/QDYRT/0025/2014,EN RELACIÓN AL SIMILAR CIDT/QDYR/3288/2013, DE FECHA 20 DICIEMBRE 2013, MEDIANTE EL CUAL SE HIZO DEL DIRECCIÓN GENERAL JURÍDICA Y CONOCIMIENTO DE UN CORREO ELECTRONICO DEL DE GOBIERNO, DIRECCIÓN 15 17 15, 15-1 07/01/2014 C. JOSE B., SOLICITA BACHEO EN LA COL. PEDREGAL GENERAL DE OBRAS Y DE SAN NICOLAS Y HEROES DE PADIERNA, DE DESARROLLO URBANO.
    [Show full text]
  • (Rituxan®), Rituximab-Abbs (Truxima®), Rituximab-Pvvr (Ruxience®) Prior Authorization Drug Coverage Policy
    1 Rituximab Products: Rituximab (Rituxan®), Rituximab-abbs (Truxima®), Rituximab-pvvr (Ruxience®) Prior Authorization Drug Coverage Policy Effective Date: 2/1/2021 Revision Date: n/a Review Date: 7/2/20 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®). Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off- Label Use of Anti-Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description1-3 Rituximab (Rituxan®), rituximab-abbs (Truxima®), and rituximab-pvvr (Ruxience®) are monoclonal antibodies that target the CD20 antigen expressed on the surface of pre-B and mature B- lymphocytes. Upon binding to cluster of differentiation (CD) 20, rituximab mediates B-cell lysis. Possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC). B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production.
    [Show full text]
  • Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease
    Pediatric Pulmonology 42:989–1001 (2007) State of the Art Pharmacotherapy of Impaired Mucociliary Clearance in Non-CF Pediatric Lung Disease. A Review of the Literature 1 1 1,2 Ruben Boogaard, MD, * Johan C. de Jongste, MD, PhD, and Peter J.F.M. Merkus, MD, PhD Summary. Mucoactive agents are used to treat a variety of lung diseases involving impaired mucociliary clearance or mucus hypersecretion. The mucoactive agents studied most frequently are N-acetylcysteine (NAC), recombinant human DNase (rhDNase), and hypertonic saline. Studies on the efficacy of these have been mainly conducted in adults, and in patients with cystic fibrosis (CF). The exact role of mucoactive agents in children with non-CF lung disease is not well established. We present an overview of the current literature reporting clinical outcome measures of treatment with NAC, rhDNase, and hypertonic saline in children. Pediatr Pulmonol. 2007; 42:989–1001. ß 2007 Wiley-Liss, Inc. Key words: mucolytic; sulfhydryl compounds; N-acetylcysteine; dornase alfa; hyper- tonic saline; respiratory tract disease. INTRODUCTION One possible means to evaluate a mucoactive agent is to assess its effect on mucociliary clearance (MCC) or cough Mucus clearance is an important primary innate airway clearance with the use of radiolabeled aerosol. Discussing defense mechanism, and our understanding of the key this subject is outside the scope of this review. Moreover, parameters underlying its function has grown rapidly in the studies on mucoactive agents in CF patients, and studies last decade.1,2 Impaired mucus clearance or mucus hyper- on physiotherapy or secretion clearance techniques in secretion are important clinical features in diseases such as (pediatric) lung disease patients have been reviewed by cystic fibrosis (CF), recurrent bronchitis, asthma, and others, and will therefore not be discussed in this review.
    [Show full text]
  • Supportive Care Medications
    th Clinical Pharmacy Guide: Cancer Drug Treatment Assessment and Review 5 Edition Supportive Care Medications Contents Introduction ................................................................................................................. 2 Supportive Care Information in Protocols .................................................................... 2 Antidiarrheals .............................................................................................................. 5 Loperamide ............................................................................................................. 5 Antiemetics .................................................................................................................. 6 Emetogenicity .......................................................................................................... 7 Types of Chemotherapy-Induced Nausea and Vomiting .......................................... 7 Classifications of Antiemetics .................................................................................. 8 Anti-infective Agents .................................................................................................. 10 Antibiotics .............................................................................................................. 10 Antivirals ................................................................................................................ 11 Arthralgias/Myalgias .................................................................................................
    [Show full text]
  • Oligodendroglial Tumor Chemotherapy Using “Decreased-Dose- Intensity”
    Oligodendroglial Abstract—The authors propose “decreased-dose-intensity” PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oli- tumor chemotherapy godendroglial tumors. In this study, all seven patients with oligodendroglioma using “decreased-dose- (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 intensity” PCV: A months (OD) and 36.5 months or greater (AO); 86% of patients with OD and Singapore experience 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted. NEUROLOGY 2006;66:247–249 A.U. Ty, MD; S.J. See, MD; J.P. Rao, MD; J.B.K. Khoo, MD, FRCR; and M.C. Wong, FRCP Oligodendroglial tumors are among the most chemo- (CR), partial response (PR), stable disease, and progressive dis- 3 ϩ sensitive of human solid malignancies. In terms of ease (PD) were used. The proportion of [CR PR] constituted the objective response rate. Progression-free survival (PFS) was the cost and availability, PCV (procarbazine, lomustine period from initiation of chemotherapy to disease progression or [CCNU], and vincristine) chemotherapy is the most death. Grade 3/4 Common Toxicity Criteria (NCI-CTC version 2.0) viable chemotherapeutic option for patients with oli- adverse events (AEs) were noted. godendroglial tumors in Asia. PCV-associated toxic- ity, particularly cumulative myelosuppression, is Results. Treatment outcome and PFS data are summa- well described among white patients.1,2 There are no rized in table 1. No patient had development of PD while reports in the published literature describing Asian undergoing chemotherapy.
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]